Feedback / Questions
IFx-2.0 - TuHURA Bio
https://www.prnewswire.com/news-releases/tuhura-biosciences-initiates-its-phase-3-accelerated-approval-trial-of-ifx-2-0-as-an-adjunctive-therapy-to-keytruda-pembrolizumab-in-first-line-treatment-for-advanced-or-metastatic-merkel-cell-carcinoma-302489200.html
Jun 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next